Abstract | PURPOSE: DESIGN: Single interventional case report. METHODS: RESULTS: CONCLUSIONS: Clinical vigilance is warranted when treating patients with anti- TNFalpha agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.
|
Authors | Jonathan C P Roos, Andrew J K Ostor |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 141
Issue 4
Pg. 767-9
(Apr 2006)
ISSN: 0002-9394 [Print] United States |
PMID | 16564827
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Amoxicillin-Potassium Clavulanate Combination
- Infliximab
- Cefotaxime
|
Topics |
- Adult
- Amoxicillin-Potassium Clavulanate Combination
(therapeutic use)
- Anti-Bacterial Agents
(therapeutic use)
- Antibodies, Monoclonal
(adverse effects)
- Cefotaxime
(therapeutic use)
- Cellulitis
(diagnosis, drug therapy, etiology)
- Drug Therapy, Combination
- Eye Infections, Bacterial
(diagnosis, drug therapy, etiology)
- Humans
- Infliximab
- Male
- Microbial Sensitivity Tests
- Orbital Diseases
(diagnosis, drug therapy, etiology)
- Randomized Controlled Trials as Topic
- Spondylitis, Ankylosing
(drug therapy)
- Staphylococcal Infections
(diagnosis, drug therapy, etiology)
- Staphylococcus aureus
(isolation & purification)
- Tumor Necrosis Factor-alpha
(immunology)
|